全球類澱粉沉積症治療市場規模、佔有率、成長分析（按最終用戶、按治療方法）- 產業預測，2024-2031 年

2022年全球類澱粉沉積症治療市場規模估值為54.6億美元，從2023年的58.7億美元成長到2031年的58.7億美元，預計在預測期內（2024-2031年）年複合成長率為7.6%。

類澱粉沉積症是一種稱為澱粉樣蛋白的蛋白質在各個器官中異常積累，可導致器官功能障礙。儘管類澱粉沉積症是一種非常罕見的疾病，但由於認知和診斷率的提高，類澱粉沉積症治療市場日益擴大。類澱粉沉積症的常見治療方法包括化療、幹細胞移植以及小分子抑制劑和單株抗體等標靶藥物。全球醫學研發支出的快速成長也推動了類澱粉沉積症藥物供應商的前景。類澱粉沉積症治療的未來市場成長也可能受到對改善患者治療結果、增加醫療保健支出、人口老化和醫療領域技術進步的日益關注的推動。由於全球對早期發現該疾病的需求不斷成長，預計在預測期內對類澱粉沉積症治療的需求將會增加。

目錄

執行摘要

• 市場概況
• 命運之輪

調查方法

• 資訊採購
• 二手資料來源和主要資料來源
• 市場規模預測
• 市場危機與限制

母市場分析

• 市場概況
• 市場規模
• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 課題

主要市場考察

• 技術分析
• 價格分析
• 供應鏈分析
• 價值鏈分析
• 市場生態系統
• 智慧財產權分析
• 貿易分析
• Start-Ups分析
• 原料分析
• 創新矩陣
• 研發線產品分析
• 總體經濟指標
• 主要投資分析
• 關鍵成功因素
• 競爭程度

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 課題
• 監管環境
• 波特的分析
• 對未來顛覆的特別見解

全球類澱粉沉積症治療市場：依最終用戶分類

• 市場概況
• 醫院
• 診所
• 研究機構

類澱粉沉積症治療的全球市場：依治療分類

• 市場概況
• 化療
• 幹細胞移植
• 症狀管理
• 新的治療方法

全球類澱粉沉積症治療市場規模：依地區

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲（MEA）
  • 海灣合作理事會國家
  • 南非
  • 其他中東、非洲

競爭格局

• 前5名企業比較
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 關鍵成功策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• Pfizer Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Alnylam Pharmaceuticals, Inc.（USA）
• Ionis Pharmaceuticals, Inc.（USA）
• Eidos Therapeutics, Inc.（USA）
• Prothena Corporation plc（Ireland）
• Akcea Therapeutics, Inc.（USA）
• Janssen Pharmaceuticals, Inc.（USA）
• GlaxoSmithKline plc（UK）
• Novartis International AG（Switzerland）
• Bristol-Myers Squibb Company（USA）
• Sanofi SA（France）
• Ionis Pharmaceuticals, Inc.（USA）
• Oncopeptides AB（Sweden）
• Alexion Pharmaceuticals, Inc.（USA）
• Celgene Corporation（USA）[Acquired by Bristol-Myers Squibb]
• Amgen Inc.（USA）
• Caelum Biosciences（USA）
• Spectrum Pharmaceuticals, Inc.（USA）
• EUSA Pharma（UK）

Global Amyloidosis Treatment Market size was valued at USD 5.46 billion in 2022 and is poised to grow from USD 5.87 billion in 2023 to USD 10.56 billion by 2031, at a CAGR of 7.6% during the forecast period (2024-2031).

Amyloidosis is the abnormal build-up of proteins called amyloids in different organs that may cause organ malfunction. Despite being an extremely uncommon ailment, the market for amyloidosis treatments is growing as a result of rising awareness and diagnostic rates. Popular treatments for amyloidosis include chemotherapy, stem cell transplantation, and targeted medicines such small molecule inhibitors and monoclonal antibodies. Future prospects for suppliers of amyloidosis treatments are also being generated by the global upsurge in spending in medical R&D. Future market growth for amyloidosis therapy might also be aided by increased attention on improving patient outcomes, growing healthcare spending, an aging population, and technological improvements in the medical field. The need for amyloidosis treatment is expected to increase over the course of the projected period due to a growing global need for early detection of the disease.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Amyloidosis Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Amyloidosis Treatment Market Segmental Analysis

The global amyloidosis treatment market can be segmented based on treatment type, end-user, and region. Based on treatment type, the market includes chemotherapy, stem cell transplant, symptomatic management, and novel therapies such as monoclonal antibodies and RNA-targeted therapies. End-users encompass hospitals, clinics, and research institutions. Geographically, the market can be divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Drivers of the Global Amyloidosis Treatment Market

Growing Prevalence of Amyloidosis: The need for amyloidosis therapy has grown due to an increase in the frequency of ATTR and AL amyloidosis worldwide. The burgeoning market for amyloidosis treatments is also being fueled by the expanding accessibility of sophisticated diagnostic techniques and rising public awareness of the disease.

Restraints in the Global Amyloidosis Treatment Market

Expensive therapy: Receiving therapy for amyloidosis can be expensive for patients, particularly if they want to use targeted medicines and other cutting-edge approaches. Long-term market growth for amyloidosis treatments is hampered by this increased cost burden.

Market Trends of the Global Amyloidosis Treatment Market

Developments in Targeted therapeutics: Research and development have made significant strides in the investigation and development of targeted therapeutics for amyloidosis. Small compounds and monoclonal antibodies were being extensively researched as possible therapies to prevent the disease's hallmark, the development or buildup of amyloid proteins. Several clinical trials were being conducted to assess the effectiveness and safety of these novel treatments.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Amyloidosis Treatment Market by End-user

• Market Overview
• Hospitals
• Clinics
• and Research Institutions

Global Amyloidosis Treatment Market by Treatment

• Market Overview
• Chemotherapy
• Stem Cell Transplant
• Symptomatic Management
• and Novel Therapies

Global Amyloidosis Treatment Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eidos Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prothena Corporation plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akcea Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oncopeptides AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alexion Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (USA) [Acquired by Bristol-Myers Squibb]
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Caelum Biosciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spectrum Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EUSA Pharma (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments